MedPageToday
MedPage Today) — SAVANNAH, Ga. — Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, missed its primary endpoint but differences emerged in other functional outcomes, the phase III EMBARK…
Read More
Gene Therapy Details Revealed in Duchenne Trial
Bong Lanz
19:40
MedPage Today) — SAVANNAH, Ga. — Delandistrogene moxeparvovec (Elevidys), a gene therapy approved to treat Duchenne muscular dystrophy, missed its primary endpoint but differences emerged in other functional outcomes, the phase III EMBARK…
